Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (Nasdaq: SUPN) plans to announce its first-quarter 2023 financial results on May 9, 2023, after market close. President and CEO Jack Khattar along with CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss these results and answer questions. The call will also be available via live webcast on the Company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system (CNS) diseases, including approved products for conditions like epilepsy and Parkinson’s disease. The company also has a pipeline of novel CNS candidates aimed at various disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) has fully repaid its 0.625% Convertible Senior Notes due 2023, amounting to $402.5 million, along with $1.3 million in interest. The repayment was financed mainly using available cash and partially through a borrowing under its credit line. With this repayment, the 2023 Notes are no longer outstanding. Supernus continues to focus on developing treatments for CNS diseases, including epilepsy and Parkinson's disease, with ongoing development of novel product candidates.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced participation in two investor conferences in March 2023. The first is the Barclays Global Healthcare Conference on March 15, 2023, at the Loews Miami Beach Hotel, Florida. The second is the Jefferies Biotech on the Bay Summit on March 16, 2023, at The 1 Hotel South Beach, Florida. These events will feature management discussions focused on the company's biopharmaceutical products for central nervous system (CNS) diseases, including treatments for epilepsy and Parkinson's disease. Investors can arrange meetings with management through conference coordinators.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that CEO Jack Khattar will participate in a fireside chat and investor meetings at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. ET. The conference runs from March 6-8, 2023, at the Boston Marriott Copley Place. Interested investors can set up meetings through the Cowen conference coordinator. A live audio webcast of Khattar's presentation will be available on Supernus' Investor Relations website, with a replay accessible for 60 days post-conference. Supernus focuses on CNS disease treatments, including epilepsy and ADHD, with ongoing development of new therapies.
Supernus Pharmaceuticals reported 2022 total revenues of $667.2 million, a 15% increase from 2021. The fourth quarter saw Qelbree® net sales of $23.6 million, up 29% from Q3, while GOCOVRI® sales reached $29.2 million, a 13% increase year-over-year. Total net product sales for the full year were $649.4 million, a 14% increase. The company anticipates 30% growth in 2023 revenues, excluding Trokendi XR® sales which face generic competition. Net earnings for Q4 stood at $25.5 million, with an EPS of $0.43.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced a new credit line agreement with UBS Bank USA, granting access to an uncommitted demand secured line of credit up to $150 million. The credit line can be drawn at any time, allowing the company to enhance its financial flexibility. Borrowing rates are determined based on either a fixed or variable interest rate linked to UBS’s funding rates. CEO Jack Khattar expressed confidence in this move to strengthen the company's balance sheet.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report its Q4 and full year 2022 financial results on February 28, 2023, after market close. The conference call with CEO Jack Khattar and CFO Tim Dec is scheduled for 4:30 p.m. ET on the same day, followed by a Q&A session. A live webcast will be available on the company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system diseases and has a diverse portfolio that includes approved therapies for various conditions such as epilepsy and Parkinson's disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its President and CEO, Jack Khattar, will participate in a fireside chat and host investor meetings at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 10:30 a.m. ET. The event will take place in New York City from November 29 to December 1, 2022. Investors can schedule meetings through the conference coordinator and access a live audio webcast on the company's website, with an archived version available for 60 days afterward.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its CEO, Jack Khattar, will present a company overview and update at two upcoming November conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15, 2022, at 8:00 a.m. ET in New York. The 13th Annual Jefferies London Healthcare Conference will take place on November 17, 2022, at 9:05 a.m. ET / 2:05 p.m. GMT in London. Interested investors can arrange meetings through conference coordinators and access live webcasts on the Company's website.
Supernus Pharmaceuticals reported total revenues of $177.4 million for Q3 2022, a 19% increase year-over-year. The company raised its full-year guidance for operating earnings to $35 million to $45 million and total revenues to $650 million to $680 million. Qelbree prescriptions rose to 94,328, a 50% increase from Q2 2022, with net product sales of $18.3 million. GOCOVRI's sales reached $27.9 million, up 16% from the previous year. Adjusted operating earnings for Q3 were $25.4 million, down from $43.3 million in 2021.